



SDI FINAL EVALUATION FORM 1.1

PART 1:

Journal Name:	Journal of Advances in Medical and Pharmaceutical Sciences
Manuscript Number:	2014_JAMPS_12818
Title of the Manuscript:	The effects of silymarin on serum soluble apoptosis markers in β -thalassemia major patients receiving desferrioxamine
Type of the Article	Short Research Article

PART 2:

FINAL EVALUATOR'S comments on revised paper (if any)	Authors' response to final evaluator's comments
I have made a lot of corrections and re-structuring in the revised manuscript. However, there some points that the authors needs to address especially areas highlighted in red .	Thank you so much for the correction of the manuscript. The required information was added to the text.
The authors should revise the conclusion of the study to correlate adequately with the aim and result of the study. More so, authors should also include an inference from the study's result in the conclusion.	The conclusion of the manuscript was revised.
Authors should provide the specific duration of the study (month and year).	The specific duration of the study was added to the text.
Authors should also provide/insert the ethical approval number for this study in the manuscript.	The ethical approval number was added to the text.
The sTNFR1 (ng/ml) level was observed to be significant in the treated group. Why it was not stated in the abstract?	Thank you so much for your comment. The result of sTNFR1 was added to the abstract.
Referencing List the first six authors followed by et al. (that is the authors are more than six) Note: Use of a DOI number for the full-text article is encouraged. (if available). Note: Authors are also encouraged to add other database's unique identifier (like PUBMED ID).	References were revised as the requested format.